Catalog No.
Product Name
Application
Product Information
Citations
-
Drug Impurity
Leflunomide impurity 7 is a known impurity associated with Leflunomide, an immunosuppressive agent. This compound is primarily utilized in research for quality control and characterization of Leflunomide formulations. It provides insights into the synthesis process and potential impacts on drug efficacy and safety profiles during pharmaceutical development. -
Drug Impurity
Tolterodine impurity 1 is a chemical impurity associated with Tolterodine, a pharmaceutical agent primarily used for the management of overactive bladder. This impurity may be utilized in research applications focused on drug formulation, stability analysis, and quality control to ensure the purity and safety of pharmaceutical products. Characterization of this impurity can aid in the understanding of Tolterodine metabolism and its potential effects on pharmacokinetics. -
Drug Impurity
Ketoprofen impurity 2 is a chemical impurity associated with Ketoprofen, a nonsteroidal anti-inflammatory drug (NSAID). This impurity can be utilized in the study of drug purity and stability, aiding in the assessment of pharmaceutical quality control. Its characterization is essential for compliance with regulatory standards in pharmaceutical development and manufacturing. -
Drug Impurity
Metformin impurity 12, also known as N2,N2-Dimethylmelamine, is a recognized impurity associated with the synthesis of Metformin. This compound is of significant interest in the study of pharmaceutical quality and safety, aiding in the assessment of drug formulations. It serves as a reference standard for analytical techniques, providing critical data for ensuring the purity and efficacy of Metformin-based medications. -
Drug Impurity
Sacubitrilat impurity 32 is an identified impurity associated with the therapeutic agent Sacubitrilat. Its presence in pharmaceutical formulations may have implications for drug quality, safety, and efficacy. This reagent is utilized in the analysis and characterization of Sacubitrilat to ensure compliance with regulatory standards and to support research in drug metabolism and pharmacokinetics. -
Drug Impurity
Edoxaban impurity 11 is a known impurity associated with the anticoagulant Edoxaban. This compound is utilized in analytical chemistry and pharmacological research to assess the purity and quality of Edoxaban formulations. Its presence can impact the safety and efficacy of drug products, making it vital for regulatory compliance and stability studies. -
Drug Impurity
Ibuprofen impurity 6, also known as p-Butylhydratropic Acid, is a recognized impurity associated with Ibuprofen. It serves as an important analytical reference for quality control and characterization in pharmaceutical formulations. This compound aids in the identification and quantification of impurities during drug development and testing processes, ensuring compliance with regulatory standards in the pharmaceutical industry. -
Drug Impurity
Rivaroxaban impurity 1 is a known drug impurity related to Rivaroxaban, a selective inhibitor of factor Xa. This impurity is critical for analytical chemistry applications, particularly in the quality control and characterization of Rivaroxaban in pharmaceutical formulations. It serves as a reference standard for assessing the purity and stability of Rivaroxaban compounds in research and development settings. -
Drug Impurity
Oxcarbazepine impurity 2 is a recognized impurity associated with the anticonvulsant drug oxcarbazepine. Its main application lies in the assessment of drug purity and quality control during the pharmaceutical development process. Understanding and characterizing this impurity is crucial for ensuring the safety and efficacy of pharmaceutical formulations containing oxcarbazepine. -
Drug Impurity
3-Methyl-2H-indazol-6-amine is a chemical compound commonly identified as a drug impurity. Its presence in pharmaceutical formulations may influence the safety and efficacy of active compounds. Research applications include the assessment of pharmaceutical quality and the study of impurity effects on drug performance and stability. -
Drug Impurity
2-(2,2,2-Trifluoroethoxy)pyridin-3-amine is identified as a drug impurity with a potential impact on drug development and safety assessments. It serves as a valuable reference standard for analytical methods such as HPLC and LC-MS. Researchers may utilize this compound to better understand the metabolic pathways and toxicity profiles of related pharmaceutical agents. -
Drug Impurity
Rivaroxaban impurity 6 is a known impurity related to the anticoagulant Rivaroxaban, acting primarily as a drug impurity marker. This compound is crucial for analytical applications, particularly in the validation and quality control of pharmaceutical formulations containing Rivaroxaban. Its presence and quantification are essential for ensuring compliance with regulatory standards in drug development and manufacturing processes. -
Drug Impurity
Cinacase impurity 12 is a chemical impurity associated with the synthesis of Cinacase. This compound is relevant in the pharmaceutical industry for quality control and assessment of drug formulations. It aids in understanding the impurity profile of Cinacase, which is essential for ensuring the safety and efficacy of the final pharmaceutical product. -
Drug Impurity
Ticagrelor impurity 11 is a known impurity associated with Ticagrelor, a potent P2Y12 adenosine diphosphate receptor antagonist. This compound may be utilized in analytical studies to assess the purity of Ticagrelor formulations, contributing to quality control and regulatory compliance in pharmaceuticals. Its characterization can provide insights into the stability and degradation pathways of Ticagrelor, aiding researchers in understanding its chemical behavior and efficacy. -
Drug Impurity
Remimazolam impurity 4 is a known impurity associated with the anesthetic compound Remimazolam. It is characterized by its potential effects on the pharmacological profile of the parent compound. This impurity is significant for research applications related to drug formulation, stability testing, and safety assessment in pharmacokinetic studies. Understanding its properties can help ensure the quality and efficacy of anesthetic products. -
Drug Impurity
Favipiravir impurity 5 is a characterized impurity of the antiviral compound Favipiravir, known for its activity against various RNA viruses. This reagent plays a critical role in the assessment of drug quality and stability during pharmaceutical development. Favipiravir impurity 5 is essential for analytical studies aimed at understanding the implications of impurities on drug efficacy and safety. -
Drug Impurity
Tofacitinib impurity 4 is a chemical impurity related to Tofacitinib, an oral Janus kinase (JAK) inhibitor. This impurity may be useful for characterization studies, quality control, and impurity profiling in the development and manufacturing of Tofacitinib. It provides valuable insights into the pharmaceutical formulation and stability of the drug, assisting researchers in ensuring safety and efficacy standards. -
Drug Impurity
Afatinib impurity 17 is a known impurity associated with Afatinib, a selective inhibitor of epidermal growth factor receptor (EGFR) tyrosine kinases. This compound is primarily used in the characterization and quality control of pharmaceutical formulations containing Afatinib. Its analysis is crucial for ensuring compliance with regulatory standards and assessing the purity of drug substances in research and development. -
Drug Impurity
Suvorexant impurity 2 is a known impurity of the sleep aid Suvorexant, functioning as a competitive antagonist of orexin receptors. This compound is primarily utilized in chemical analysis and quality control of Suvorexant formulations, as well as in the study of drug metabolism and stability. Its presence is critical for ensuring the purity and efficacy of pharmaceutical products containing Suvorexant. -
Drug Impurity
(S)-Cinacalcet hydrochloride is a drug impurity associated with cinacalcet, a calcimimetic agent that targets the calcium-sensing receptor. This compound is primarily utilized in research to study drug metabolism, stability, and safety profiles of cinacalcet formulations. Its analysis is critical for ensuring the quality and regulatory compliance of pharmaceutical developments. -
Drug Impurity
Rivastigmine impurity 12 (m-Methoxyacetophenone) is a known impurity associated with Rivastigmine, an acetylcholinesterase inhibitor used in the treatment of Alzheimer's disease. This compound serves as a valuable reference material for analytical chemistry applications, particularly in the development and validation of analytical methods for drug quality control. Its characterization contributes to ensuring the safety and efficacy of pharmaceutical formulations containing Rivastigmine. -
Drug Impurity
Acetazolamide impurity 2 (NSC 231656) is characterized as a minor impurity of the carbonic anhydrase inhibitor, Acetazolamide. This compound is relevant for quality control and assurance in pharmaceutical formulations, particularly for studies assessing the purity and stability of Acetazolamide. Its identification and quantification may facilitate research on drug efficacy and safety in various therapeutic applications. -
Drug Impurity
Pregabalin impurity 3 is a recognized impurity associated with the drug Pregabalin, which primarily targets voltage-gated calcium channels. This compound may play a role in understanding the metabolic pathways and degradation processes of Pregabalin. Research applications of Pregabalin impurity 3 include method development for impurity analysis in pharmaceuticals and exploring potential interactions that could affect drug safety and efficacy. -
Drug Impurity
Rivaroxaban impurity 70 is a chemical impurity associated with the anticoagulant Rivaroxaban. This compound is primarily used in pharmaceutical research to investigate the safety, efficacy, and quality of Rivaroxaban formulations. Its characterization is essential for compliance with regulatory standards and the development of robust drug manufacturing processes. -
Drug Impurity
Pramipexole impurity 9 is a chemical impurity associated with Pramipexole, a dopamine D2 receptor agonist used in the treatment of Parkinson's disease and restless legs syndrome. This impurity is relevant for analytical studies and quality control in pharmaceutical development, particularly in assessing the purity of Pramipexole formulations. Its characterization aids in understanding the stability and metabolism of the primary compound, ensuring safety and efficacy in therapeutic applications. -
Drug Impurity
Glycopyrronium impurity 6 is a chemical impurity associated with Glycopyrronium, a medication utilized for its anticholinergic properties. This impurity is relevant for quality control and analytical chemistry applications in pharmaceutical development. Its characterization is essential for ensuring the purity and efficacy of Glycopyrronium formulations in drug research and regulatory compliance. -
Drug Impurity
Ramipril Impurity 10 is a byproduct of Ramipril, a well-known angiotensin-converting enzyme (ACE) inhibitor. This impurity serves as a critical reference standard in pharmaceutical quality control and formulation development. Its characterization is essential for ensuring the integrity and safety of Ramipril-containing formulations in various research applications. -
Drug Impurity
Norepinephrine tartrate impurity 33 is an identified impurity associated with the adrenergic neurotransmitter norepinephrine tartrate. This compound may be utilized in pharmaceutical development and quality control assays to assess the purity of norepinephrine formulations. Its presence and characterization are crucial for ensuring compliance with regulatory standards and maintaining the integrity of therapeutic preparations. -
Drug Impurity
Rivaroxaban impurity 71, also known as N-Methylphthalimide, is a chemical impurity associated with Rivaroxaban synthesis. It serves as a reference standard for quality control and analytical studies in pharmaceutical development. This compound is critical for ensuring the purity and safety of Rivaroxaban formulations, facilitating research on drug efficacy and stability. -
Drug Impurity
Ribociclib impurity 5 is a specific impurity associated with Ribociclib, a selective inhibitor of cyclin-dependent kinases 4 and 6 (CDK4/6). This compound serves important roles in the quality control and characterization of ribociclib formulations. Its presence may impact drug efficacy and safety profiles, making it relevant for pharmacological and toxicological studies. Researchers can utilize Ribociclib impurity 5 to ensure analytical rigor in drug development and formulation testing. -
Drug Impurity
Ribociclib impurity 3 is a known impurity associated with Ribociclib, an FDA-approved cyclin-dependent kinase (CDK) inhibitor. This compound serves as a valuable reference material for the characterization and quality control of Ribociclib formulations. It is essential for analytical research and development, particularly in pharmacokinetic studies and stability assessments of CDK inhibitors. -
Amide Impurity
Citalopram impurity 1 is an amide impurity that arises during the synthetic production of Citalopram. This compound can be utilized in quality control and analytical studies to assess the purity of Citalopram formulations. It serves as an important reference material for researchers engaged in pharmacological studies and drug development processes involving Citalopram. -
Irinotecan Hydrochloride Impurity
8-Ethyl Irinotecan is identified as an impurity of Irinotecan hydrochloride, acting primarily as a topoisomerase I inhibitor. This compound is relevant for research applications aimed at understanding the metabolic pathways and pharmacokinetics of Irinotecan, as well as evaluating its efficacy and safety profiles in cancer treatment studies. Investigating this impurity can provide valuable insights into the potential impacts on drug formulation and therapeutic outcomes. -
Drug Impurity
Nimesulide impurity 3, or 4-Nitro-2-phenoxyaniline, is a known impurity associated with the synthesis of Nimesulide. This compound is important for quality control and characterization in pharmaceutical research, particularly in the evaluation of drug purity and safety. Its role as a metabolite in toxicological studies makes it relevant for assessing the pharmacokinetics and potential side effects of Nimesulide. -
Drug Impurity
Irbesartan impurity 8 is a known impurity associated with the drug Irbesartan, an angiotensin II receptor antagonist. This compound is primarily used for quality control and analytical purposes in pharmaceutical research and development. Its presence can provide insights into the synthesis and stability of Irbesartan formulations. -
Drug Impurity
Aripiprazole impurity 34 is a chemical impurity associated with the antipsychotic drug Aripiprazole. This compound serves as an important reference standard in pharmaceutical research, particularly in studies focusing on drug composition and quality control. It aids in the assessment of purity levels and can be utilized in stability testing and regulatory submissions. Researchers can leverage this impurity to ensure consistent quality in Aripiprazole formulations. -
Drug Impurity
Budesonide impurity 83, also known as Budesonide 21-butyrate, is a specific impurity derived from Budesonide. Its characterization is essential for ensuring the quality and safety of pharmaceutical formulations. This compound serves as a reference standard in analytical chemistry, assisting in method development and validation for the detection of Budesonide-related substances in drug production. -
Drug Impurity
Leflunomide impurity 4 is a known impurity associated with Leflunomide, an immunomodulatory drug. It is utilized in the study of drug metabolism and pharmacokinetics, facilitating the assessment of purity standards in pharmaceutical formulations. This reagent is essential for quality control and regulatory compliance in drug development processes. -
Drug Impurity
Estradiol Valerate Impurity 5 is a chemical impurity associated with Estradiol Valerate. This compound serves as a critical reference standard for assessing the purity and quality of Estradiol Valerate formulations in pharmaceutical research. It is essential for analytical method development, stability testing, and compliance with regulatory standards in drug manufacturing processes. -
Drug Impurity
Trimetazidine impurity 8 is a known impurity associated with the pharmaceutical compound Trimetazidine. It is used primarily for analytical and research purposes, particularly in the characterization and quality control of Trimetazidine formulations. The identification and quantification of impurities like Trimetazidine impurity 8 are essential for ensuring the safety and efficacy of drug products in compliance with regulatory standards. -
Drug Impurity
Montelukast impurity 1 hydrochloride is a known impurity of the leukotriene receptor antagonist Montelukast hydrochloride. This compound may serve as a reference standard for the assessment of Montelukast's purity in pharmaceutical formulations. Its analysis is crucial for quality control in drug development and regulatory compliance. -
Drug Impurity
Duloxetine impurity 3 hydrobromide is a specific impurity related to Duloxetine hydrobromide, primarily utilized in chemical research and pharmaceutical quality control. Its characterization is crucial for ensuring the purity and safety of Duloxetine formulations. This compound serves as a reference standard in studies focused on drug development, stability testing, and impurity profiling for regulatory compliance. -
Drug Impurity
Salbutamol Impurity 1, also known as Salbutamol Impurity G, is a known impurity associated with the compound Salbutamol. This reagent is utilized primarily in pharmaceutical research to assess the purity and stability of Salbutamol formulations. Its presence is critical for quality control and regulatory compliance in the development of bronchodilator therapies. -
Drug Impurity
Clarithromycin impurity 7, also known as N-Formylclarithromycin, is a recognized impurity of the antibiotic agent Clarithromycin. This compound is utilized primarily in quality control and analytical studies to assess the purity of Clarithromycin formulations. Its presence can affect the efficacy and safety profiles of the primary drug, making it important for pharmaceutical research and development. -
Drug Impurity
2-Oxo-2-(10,13,16-trimethyl-3-oxo-17-(propionyloxy)-6,7,8,10,12,13,14,15,16,17-decahydro-3H-cyclopenta[a]phenanthren-17-yl)ethyl propionate is an impurity associated with Beclomethasone Dipropionate. This compound is utilized primarily in the quality control and characterization of pharmaceutical formulations containing corticosteroids. Its determination is essential for ensuring the purity and efficacy of therapeutic agents in the clinical setting. -
Drug Impurity
Dexamethasone acetate impurity 2, also known as Desoxymetasone 21-Acetate, is identified as a drug impurity associated with Dexamethasone acetate. It serves as a critical reference standard for assessing the purity and quality of pharmaceutical formulations. Research applications include the study of drug stability, formulation development, and regulatory compliance in pharmaceutical manufacturing processes. -
Drug Impurity
Rufinamide impurity 6 is a relevant impurity associated with the antiepileptic drug Rufinamide. This compound may be utilized in analytical research to study the purity and stability of Rufinamide formulations. Its characterization is essential for ensuring compliance with regulatory standards in pharmaceutical development. -
Drug Impurity
Levothyroxine impurity 8 is a known impurity related to Levothyroxine, a synthetic form of the thyroid hormone thyroxine (T4). This compound is crucial for assessing the purity and quality of Levothyroxine in pharmaceutical formulations. It is commonly used in analytical research to ensure compliance with regulatory standards and to investigate the potential effects of impurities on biological activity. -
Drug Impurity
Fenirofibrate impurity 4 is a chemical impurity associated with Fenirofibrate, a lipid-regulating agent. This impurity can be used in analytical studies for purity assessment and quality control during pharmaceutical research and development. Its presence in formulations may affect the overall safety and efficacy profiles of the primary compound, making it crucial for researchers engaged in drug formulation and compliance testing. -
Drug Impurity
Carbamazepine impurity 5 is a known impurity of the anticonvulsant drug Carbamazepine. This compound serves as a reference standard for impurity profiling and quality control in pharmaceutical research. Its characterization is essential for understanding the drug's stability, efficacy, and safety profile in therapeutic applications.
